Research Analysts Set Expectations for FENC Q1 Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Equities research analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of Adherex Technologies in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.02) per share for the quarter, down from their previous forecast of $0.07. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q2 2026 earnings at $0.05 EPS, FY2026 earnings at $0.31 EPS, Q1 2027 earnings at $0.17 EPS and Q2 2027 earnings at $0.22 EPS.

Adherex Technologies (NASDAQ:FENC) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.21). Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%. The business had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.75 million.

Other research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Wall Street Zen downgraded Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 25th. Piper Sandler initiated coverage on Adherex Technologies in a report on Friday, January 9th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, B. Riley Financial assumed coverage on Adherex Technologies in a research report on Thursday, February 12th. They set a “buy” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Adherex Technologies presently has an average rating of “Moderate Buy” and an average price target of $15.25.

Adherex Technologies Stock Performance

FENC opened at $6.15 on Wednesday. The company has a fifty day moving average price of $7.77 and a two-hundred day moving average price of $8.04. The firm has a market capitalization of $211.99 million, a PE ratio of -18.09 and a beta of 0.75. Adherex Technologies has a 52 week low of $4.68 and a 52 week high of $9.92.

Insider Activity

In related news, Director Rosty Raykov sold 10,349 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $7.76, for a total value of $80,308.24. Following the completion of the sale, the director owned 98,477 shares in the company, valued at $764,181.52. This represents a 9.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Adherex Technologies News Roundup

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: Analysts give a “Moderate Buy” consensus for Adherex, which can support the stock as investors weigh the outlook versus the recent miss. Article Title
• Positive Sentiment: HC Wainwright issued a multi‑quarter and FY2027 outlook that is materially positive (FY2027 EPS forecast of ~$0.96, with Q3/Q4 2027 estimates at $0.26 and $0.30), suggesting significant expected earnings improvement over the next 12–24 months. Analyst Note
• Neutral Sentiment: The company approved inducement stock option awards (377,500 ISOs to 24 new non‑executive employees) under Nasdaq rules — signals hiring/retention but also potential future dilution; watch grant strike prices and vesting. Press Release
• Negative Sentiment: Earnings miss: Adherex reported ($0.17) EPS vs. a $0.04 consensus and revenue of $13.78M vs. $14.75M expected — the miss and negative margins/ROE are the primary near‑term drivers pushing the stock lower. Listen to the conference call and review the release for management’s commentary on guidance and cost actions. Earnings Transcript Press Release
• Negative Sentiment: HC Wainwright reduced near‑term EPS forecasts for Q3 and Q4 2026 (Q3: from $0.19 to $0.12; Q4: from $0.24 to $0.16), which increases short‑term uncertainty despite their optimistic longer‑term view. Analyst Revision

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.